Chiesi Group, a global biopharmaceutical company headquartered in Parma, Italy, announced that it has chosen Salesforce’s Agentforce Life Sciences platform to overhaul its commercial operations and strengthen engagement with healthcare professionals worldwide.
The new platform will be integrated with Salesforce Data 360 and Marketing Cloud, creating a unified data foundation that enables AI‑driven, compliant interactions across sales, marketing, and service teams. This integration is intended to improve collaboration, accelerate digital transformation, and support regulatory compliance in the highly regulated life‑sciences market.
Salesforce’s Agentforce is part of its “Agentic Enterprise” strategy, which uses AI to automate tasks, reason, and act within regulated environments. By deploying Agentforce, Chiesi gains a scalable foundation for sustainable growth and a more connected, responsive approach to patient‑centric care.
The partnership fits into Chiesi’s broader digital‑transformation agenda, which includes a migration to SAP S/4HANA Cloud. Together, the new Salesforce stack and the SAP migration position Chiesi to deliver better patient outcomes through more efficient, data‑driven commercial operations.
The deal underscores Salesforce’s push into regulated life sciences, adding a high‑profile customer and reinforcing its competitive moat in the enterprise‑software market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.